25. Cytotoxic Tumor Targeting With scFv Antibody-Modified Liposomes
| Abstract |
|
|
Specific targeting of liposome-formulated cytotoxic drugs or antigens to receptors expressed selectively on target cells represents
an effective strategy for increasing the pharmacological efficacy of the delivered molecules. We have developed a feasible
technique to selectively attach antibodies and fragments thereof, but also small-mol-wt ligands such as peptides, carbohydrates,
or any molecules that recognize and bind target antigens or receptors to the surface of small unilamellar liposomes. Our concept
is based on the site-specific functionalization of the ligands to be attached to the liposomes by thiol groups. These thiol
groups can easily be introduced to antibodies or peptides by addition of cysteines, preferably at sites that do not interfere
with the receptor binding domains. Optimally, the site-specific modification is introduced at the C-terminal end of the ligand,
separated by an inert spacer sequence located between the thiols and the specific part of the ligand. The thiol-reactive molecules
on the liposome surface are maleimides that are linked to phospholipids composing the liposome bilayer membrane. We illustrate
the coupling method of a functionalized single-chain antibody fragment with binding specificity to ED-B fibronectin, an isoform
of fibronectin exclusively expressed in tumor tissues, to long circulating small unilamellar poly(ethylene glycol) liposomes.
Affiliation(s): (3) Molecular Cell Biology, Paul Scherrer Institute, Villigen, Switzerland
(4) Paul Scherrer Institute, Molecular Cell Biology, Villigen, Switzerland
(4) Paul Scherrer Institute, Molecular Cell Biology, Villigen, Switzerland
Book Title: Adoptive Immunotherapy: Methods and Protocols
Series: Methods in Molecular Medicine | Volume: 109 | Pub. Date: Nov-30-2004 | Page Range: 389-401 | DOI: 10.1385/1-59259-862-5:389
Subject: Immunology
Key Words: Ligand-mediated liposome targeting - site-directed ligand modification - ligand functionalization - liposomes - immunoliposomes - thiol-maleimide coupling - cysteine modification - single-chain antibody fragment - peptides - targeted tumor therapy - vaccines
Comments (Loading...) |
||
Loading... |





















